FDA opens preliminary inquiry into risks of epilepsy drugs

The FDA has begun an inquiry into whether epilepsy drugs may increase the risk of suicidal behavior in some patients, with a focus on those who use them for psychiatric illnesses.
The inquiry was prompted in part by a lawyer's claims against the leading anti-convulsant, Neurontin. The FDA last month asked makers of all epilepsy drugs to re-examine research to see if there was evidence of increased suicide risk.
Robert Temple, the agency's drug policy chief told the Associated Press, "I don't think we have any suspicion yet that these drugs actually do that."
The analysis is the same as what the agency ordered last year for antidepressants amid controversy over their use by children and teenagers.
Ultimately, those drugs were linked to an increase in suicidal thoughts and actions in a small fraction of young patients.

 

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.